Article Tools

Serious setback for Intercell

Published: December 14, 2010; 15:16 · (Vindobona)

The Vienna vaccine manufacturers has to terminate a research project unexpectedly at a late stage. Heavy losses are expected for this year.

Serious setback for Intercell / Picture: © Vindobona.org

Intercell has to terminate its program to develop a vaccine patch to stop travelling diarrhea. The clinical studies, contrary to expectations, promised too little protection against the travelling sickness. The costly project was already at a late stage of development. High write-off costs are the result: extraordinary expenses for € 167m are expected. Even if not the entire…

This article includes a total of 190 words.

or Log In